Immunocore Holdings plc (IMCR) Profit Margins
Over the twelve months to 2026-06-30, Immunocore Holdings plc (IMCR) had operating margin -5.2%, net margin -4.2%, free cash flow margin -9.6%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IMCRImmunocore Holdings plcFollow IMCR — free
—
Price chart with a free account
- Market cap
- 1.6B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Gross margin | 99.6% | 99.1% | 98.7% | — | |
| Operating margin | -23.9% | -22.7% | -11.3% | -5.2% | |
| Net margin | -22.2% | -16.5% | -8.9% | -4.2% | |
| FCF margin | -1.0% | 6.7% | -3.8% | -9.6% |
USD billions · SEC XBRL
Immunocore Holdings plc — questions
- What is Immunocore Holdings plc's operating margin?
- -5.2% over the twelve months to 2026-06-30.
- What is Immunocore Holdings plc's net profit margin?
- -4.2% over the twelve months to 2026-06-30.
Every figure on this page comes from Immunocore Holdings plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.